Your trusted source for facts... where we dissect the evidence behind risky rumors and reveal clinical truths.
This podcast series from TRC Healthcare, the team behind Pharmacistâs Letter, Pharmacy Technicianâs Letter,and Prescriber Insights products, is designed to help pharmacists, pharmacy technicians, prescribers, and even patients navigate some of the claims they might see about medication therapy.Â
Find the video version of this show on YouTube: https://www.youtube.com/@trc.healthcareÂ
TRC Healthcare offers CE credit for this podcast for subscribers at our platinum level or higher. Log in to your Pharmacistâs Letter, Pharmacy Technicianâs Letter,or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.
Generic drugs save money, but do they lower the bar?Â
From what "bioequivalent" really requires to why an authorized generic can look just like the brand name, a lot of what gets assumed about generic drugs hasn't caught up with how tightly this corner of pharmacy is actually regulated.Â
In this episode, Don and Steve pick apart the claims pharmacists hear most about generic drugs.
đŹ Do generics really get held to a lower approval or quality bar than the brand drug?
đŠ Is an authorized generic just the brand drug repackaged in a different box?
đ Is it safe to switch between generics from different manufacturers?
đ Are generic drug names really just made up?Â
We'll check the label on the evidence and find out which generic claims are the real deal:
Generics have lower approval and quality standards.
Authorized generics are the same product as the brand drug.
Switching between generics is safe.
Generic drug names are just made up.
đ·ïž Our listeners can get 10% off a new or upgraded subscription with code rvt1026 at checkout.Â
******
TRC Healthcare Editor Hosts:Â
Stephen Small, PharmD, BCPS, BCPPS, BCCCP, CNSCÂ
Don Weinberger, PharmD, PMSP
******
Guest:Â
Doug Hoey, RPh, MBA (Chief Executive Officer of the National Community Pharmacists Association, NCPA)
******
CE Information:
None of the speakers have anything to disclose.Â
TRC Healthcare offers CE credit for this podcast for subscribers at our platinum level or higher. Log in to your Pharmacistâs Letter, Pharmacy Technicianâs Letter,or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.
The clinical resources mentioned during the podcast are part of a subscription to Pharmacistâs Letter, Pharmacy Technicianâs Letter, and Prescriber Insights:Â
Naloxone and nalmefene are reaching more hands than everâthrough bystander programs, pharmacy dispensing protocols, and over-the-counter sales. But as access expands, one question keeps coming up:
Does easier access to naloxone or nalmefene actually make opioid misuse worse?
In this BONUS mailbag episode of Rumor vs Truth, we answer a listener question about whether increasing naloxone and nalmefene access encourages opioid misuse or overdose. Hosts Don Weinberger, PharmD, and Steve Small, PharmD, bring in addiction medicine specialist Dr. Nicole Gastala, MD, to unpack what the evidence actually shows.
Together, they discuss:
Whether increasing naloxone or nalmefene access actually encourages riskier opioid use
What a large systematic review and 2025 American Heart Association guidance say about public-access naloxone
Why carrying naloxone is more like carrying an EpiPen than a âpermission slipâ for risk
The one real risk to watch for after a reversal: precipitated withdrawal
Why OTC naloxone and statewide pharmacy dispensing protocols matter for practice
No CE credit is available for this bonus episode. Want the full breakdown? CE credit is available for our full episode on opioids.
******
đ§ Related Episode (CE Available)
Rumor vs Truth: Laxatives (Opioid FACTS OR FEARS?) đ§Listen: https://rumorvstruth.buzzsprout.com/episodes/19647733 â¶ïž Watch: https://youtu.be/sl3upSCxfwMÂ
Opioid Rules of Thumb Are StickyâEven When the Evidence Moves On.Â
From how quickly dependence risk starts to whether the newest non-opioid really replaces an opioid, a lot of advice is still running on assumptions learned years ago.Â
In this episode, Don and Steve separate opioid fact from folklore by challenging long-held assumptions with the latest evidence. Â
đ How fast can dependence risk start after a first prescription?Â
đ Does suzetrigine (Journavx) give opioids a run for their money with safety?Â
We'll titrate the puns and press on a few pain points to get to the truth behind these claims:Â
Dependence risk can increase soon after initiating opioids.Â
Suzetrigine is safer than opioids.Â
Antihistamines are very effective for opioid-induced pruritus (itching).Â
Patients with opioid use disorder (OUD) cannot be treated with opioids for pain.Â
đ·ïž Our listeners can get 10% off a new or upgraded subscription with code rvt1026 at checkout. Â
******Â
TRC Healthcare Editor Hosts: Â
Stephen Small, PharmD, BCPS, BCPPS, BCCCP, CNSC Â
Don Weinberger, PharmD, PMSPÂ
******Â
CE Information:Â
None of the speakers have anything to disclose.Â
TRC Healthcare offers CE credit for this podcast for subscribers at our platinum level or higher. Log in to your Pharmacistâs Letter, Pharmacy Technicianâs Letter,or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.Â
BONUS: Mailbag - Do Patients Need to Separate Miralax From Other Medications?
Can polyethylene glycol (PEG 3350, Miralax) affect the absorption of other medications?
In this BONUS mailbag episode of Rumor vs Truth, we answer a listener question about whether polyethylene glycol (PEG 3350) should be separated from other medications and, if so, by how long. Hosts Don Weinberger, PharmD and Steve Small, PharmD break down what the evidence actually shows about laxatives, intestinal transit time, and medication absorption.
Together, they discuss:
Can PEG 3350 reduce the absorption of certain medications?
Which medications might warrant extra caution when taken with PEG 3350?
When spacing PEG 3350 doses may be reasonable...and when it may be unnecessary
Practical counseling tips to balance adherence with potential interaction concerns
No CE credit is available for this bonus episode. Want the full breakdown? CE credit is available for our full episode on laxatives.
The Constipation Conversation Has Been Backed Up for Years.
From fears about laxative dependence to questions about pediatric safety, some laxative myths are still stuck in the system⊠despite growing evidence to the contrary.
In this episode, Don and Steve tackle some of the most common claims healthcare professionals hear about constipation treatmentâand explore what the research really says.Â
đ€° Are magnesium-based laxatives really unsafe during pregnancy?
Weâll leave no stool unturned as we get to the bottom of these claims:
Oral docusate isnât an effective laxative.
Chronic stimulant laxatives damage the gut.
PEG 3350 causes autism and behavioral changes in kids.
Magnesium-based laxatives arenât safe to use in pregnancy.
đ·ïž Our listeners can get 10% off a new or upgraded subscription with code rvt1026 at checkout.Â
******
TRC Healthcare Editor Hosts:Â
Stephen Small, PharmD, BCPS, BCPPS, BCCCP, CNSCÂ
Don Weinberger, PharmD, PMSP
******
Guest:Â
Nina Pascua, MD, PharmD, MSCE, MBA
******
CE Information:
None of the speakers have anything to disclose.Â
TRC Healthcare offers CE credit for this podcast for subscribers at our platinum level or higher. Log in to your ,or account and look for the title of this podcast in the list of available CE courses.
BONUS: Mailbag - Can Ivermectin be used in all kids?
Ivermectin continues to come up in patient conversationsâand not just for adults.
Can ivermectin now be used safely in all kids after the recent KIDs List update?
In this BONUS mailbag episode of Rumor vs Truth, we answer a listener question about ivermectin use in kids. Hosts Don Weinberger, PharmD and Steve Small, PharmD break down what actually changed with ivermectin in the 2025 update to the KIDs Listâand what it does (and doesnât) mean for clinical practice. This âkid-sizedâ question packs a bigger clinical punch than you might expect.
Together, they discuss:
What actually drove the KIDs List change
Where the supporting evidence is strongâand where itâs limited
Why âremoved from the listâ â âsafe for all kidsâ
How to apply this update in real-world pediatric decisions
No CE credit is available for this bonus episode. Want the full breakdown? CE credit is available for our full episode on ivermectin.
Ivermectin Is Back in the ConversationâBut What Should Healthcare Teams Know?
From expanded OTC access in some states to persistent online claims, ivermectin is once again popping up in patient conversationsâand bringing plenty of confusion with it.
In this episode, Don and Steve dig into whatâs driving the buzz and what the evidence actually shows across a surprisingly wide range of uses. From viral misinformation to emerging global health research, they explore where ivermectin fits⊠and where it doesnât.
Along the way, they tackle one of the biggest challenges in practice: how to respond when patients ask about therapies fueled more by headlines than high-quality dataâand how to keep those conversations grounded, practical, and patient-centered. Plus, they feature insights from an oncology specialist on real-world patient scenarios.
đŠ Is ivermectin still being used for COVID-19âand what does the latest evidence really show?
đ§Ź How should healthcare professionals respond to patients asking about ivermectin for cancer?
đ When might oral ivermectin make sense for certain conditions, like rosacea?
đ Could ivermectin help reduce malaria transmissionâand why does context matter?
Letâs worm through the data and track down what holds upâand what doesnât.
They put these claims under the microscope:
Ivermectin prevents and cures COVID-19.
Ivermectin prevents and cures cancer.
Oral ivermectin may improve rosacea.
Ivermectin can reduce malaria transmission.
đ·ïž Our listeners can get 10% off a new or upgraded subscription with code rvt1026 at checkout.Â
Gabapentin is showing up more often in veterinary care âbut that raises an important question:
Is gabapentin toxic in animals?
In this BONUS mailbag episode of Rumor vs Truth, we answer a listener question about gabapentin use in pets. Hosts Don Weinberger, PharmD and Steve Small, PharmD dig into whatâs really behind concerns about toxicityâand bring in veterinary toxicology expert Dr. Tina Wismer to help clarify the risks.
Together, they discuss:
Why gabapentin is used in dogs and cats
Where these toxicity concerns come from
The role of xylitol in certain liquid formulationsâand why this matters
Why dogs, but not cats, are affected by xylitol
What pharmacists and clinical teams should watch for when dispensing
What pet owners should do if exposure is suspected
No CE credit is available for this bonus episode. CE credit is available for our full gabapentin episode.
Gabapentin has become a go-to option across a wide range of clinical scenariosâbut how well does it actually hold up under closer scrutiny?
In this episode, Don Weinberger and Steve Small take a closer look at how gabapentin performs in real-world useâand where expectations may not match the data.
đ§ Does gabapentin meaningfully improve neuropathic pain outcomesâor are we overestimating its impact in everyday practice?
â ïž How should clinicians interpret safety concerns like dependence, cognitive effects, and mood changes when counseling patients?
đ Are we using gabapentin for the right types of painâor defaulting to it when evidence is limited?
Weâll break down the data, challenge common assumptions, and follow the evidence wherever it leadsâso you can separate clinical signal from background noise when evaluating gabapentin.
Key claims explored in this episode include:
Gabapentin is modestly effective for neuropathic pain
Gabapentin is addictive
Gabapentin causes dementia
Gabapentin is associated with suicidal behavior
Youâll also get quick clinical insights on:
Cardiovascular risk signals linked to gabapentin use
Whether gabapentin plays a role in treating anxiety disorders
đ·ïž Our listeners can get 10% off a new or upgraded subscription with code rvt1026 at checkout.Â
******
TRC Healthcare Editor Hosts:
Stephen Small, PharmD, BCPS, BCPPS, BCCCP, CNSCÂ
Don Weinberger, PharmD, PMSP
******
Guest:Â
Adam Kaye, PharmD, FASCP, FCPhA
******
CE Information:
BONUS: Mailbag - Should patients stop antibiotics early if they feel better?
Shorter antibiotic courses are becoming the normâbut that raises an important question we hear all the time:
Can patients stop antibiotics early once they start feeling better?
In this BONUS mailbag episode of Rumor vs Truth, we step outside our regular format to answer a single listener question submitted through our fan mail audio line. Hosts Don Weinberger, PharmD and Steve Small, PharmD revisit antimicrobial stewardship and bring back infectiousâdiseases pharmacist Dr. Madeline King to break down what the evidence really tells us.
Together, they discuss:
Why antibiotic durations have shortened over time
Whether stopping early increases the risk of resistance
Why âfeeling betterâ doesnât always mean the infection is resolved
When stopping early might be reasonableâand why that decision should still come from the prescriber
How pharmacists and clinicians can frame these conversations with patients
No CE credit is available for this bonus episode. CE credit is available for our full episode on antimicrobial stewardship.
The clinical resources mentioned during the podcast are part of a subscription to Pharmacistâs Letter, Pharmacy Technicianâs Letter, and Prescriber Insights: Â
The clinical resources mentioned during the podcast are part of a subscription to Pharmacistâs Letter, Pharmacy Technicianâs Letter, and Prescriber Insights:Â
TRC Healthcare offers CE credit for this podcast for subscribers at our platinum level or higher. Log in to your Pharmacistâs Letter, Pharmacy Technicianâs Letter,or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.
The clinical resources mentioned during the podcast are part of a subscription to Pharmacistâs Letter, Pharmacy Technicianâs Letter, and Prescriber Insights:Â
TRC Healthcare offers CE credit for this podcast for subscribers at our platinum level or higher. Log in to your Pharmacistâs Letter, Pharmacy Technicianâs Letter,or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.
The clinical resources mentioned during the podcast are part of a subscription to Pharmacistâs Letter, Pharmacy Technicianâs Letter, and Prescriber Insights:Â